S&P ASX All Technology

US Dollar vs AUD

Register to chat with like-minded investors on our interactive forums.

Get Started

ACRV Acrivon Therapeutics Inc

8.40

-0.07 (-0.83%)

Pre Market

Last Updated: 19:40:35

Delayed by 15 minutes

Sec Staff Action/letter (sec Staff)

This regulatory filing also includes additional resources:
filename1.pdf

Acrivon Therapeutics (NASDAQ:ACRV)
Historical Stock Chart
From Mar 2024 to Apr 2024

Click Here for more Acrivon Therapeutics Charts.

Acrivon Therapeutics (NASDAQ:ACRV)
Historical Stock Chart
From Apr 2023 to Apr 2024

Click Here for more Acrivon Therapeutics Charts.

Acrivon Therapeutics, Inc. News

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
Thursday 25 April 2024 (2 days ago) • GlobeNewswire Inc.

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
Wednesday 17 April 2024 (1 week ago) • GlobeNewswire Inc.

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistanc
Wednesday 10 April 2024 (2 weeks ago) • GlobeNewswire Inc.

Acrivon Therapeutics Announces $130 Million Private Placement Financing
Tuesday 9 April 2024 (2 weeks ago) • GlobeNewswire Inc.

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Thursday 28 March 2024 (4 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 7 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Thursday 7 March 2024 (2 months ago) • Edgar (US Regulatory)

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
Wednesday 6 March 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)

Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
Tuesday 5 March 2024 (2 months ago) • GlobeNewswire Inc.

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
Wednesday 28 February 2024 (2 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 17 February 2024 (2 months ago) • Edgar (US Regulatory)

More Acrivon Therapeutics, Inc. News Articles

Newcrest Mining

Australian SE All Ordina...

Woodside Petroleum

AUD vs US Dollar

National Australia Bank

JP Morgan Chase

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions